高级检索
当前位置: 首页 > 详情页

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pharm, Wuhan, Hubei, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Hubei, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China [4]Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 500 W 12Th Ave, Columbus, OH 43210 USA
出处:
ISSN:

关键词: liposome doxorubicin folate ligand FR-targeting stability

摘要:
Instability of targeting ligand is a roadblock towards successful development of folate targeted liposomes. Folate ligands have been linked to polyethylene glycol (PEG) and cholesterol by an amide bond to form folate-CONH-PEG-CONH-Cholesterol (F-CONH-PEG-CONH-Chol), which is subject to hydrolysis. To increase the stability of folate ligands and promote the long circulation and targeting effects, we synthesized a chemically stable lipophilic folate derivative, folate-CONH-PEG-NH-Cholesterol (F-CONH-PEG-NH-Chol), where the amide bond was replaced by a C-N bond, to deliver liposomal doxorubicin (Dox). Its physical stability, cellular uptake, cellular toxicity, pharmacokinetics, distribution, anti-tumor efficacy, and cardiac toxicity were investigated. Our results indicate that F-CONH-PEG-NH-Chol conjugated liposomes are taken up selectively by folate receptor-positive HeLa and KB cells. Compared with F-CONH-PEG-CONH-Chol with two carbonate linkages, F-CONH-PEG-NH-Chol better retained its drug entrapment efficiency and folate receptor-targeting activity during prolonged circulation. F-CONH-PEG-NH-Chol thus represents a physically stable and effective ligand for delivering folate receptor-targeted liposomes, with prolonged circulation time and efficient tissue distribution, as well as higher efficacy and less cardiac toxicity. Collectively, these results suggest that this novel conjugate can serve as a promising derivative for the delivery of antitumor therapeutic agents.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 2 区 工程技术
小类 | 3 区 纳米科技 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 纳米科技
JCR分区:
出版当年[2012]版:
Q1 PHARMACOLOGY & PHARMACY Q2 NANOSCIENCE & NANOTECHNOLOGY
最新[2023]版:
Q1 NANOSCIENCE & NANOTECHNOLOGY Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pharm, Wuhan, Hubei, Peoples R China
通讯作者:
通讯机构: [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Hubei, Peoples R China [*1]Tongji Med Coll, S chool Pharm, Hangkong Rd 13, Wuhan 430030, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)